Loading...
SANDOZ (A Novartis Division)
About Company
Our Vision is to be the world’s leading and most valued generics and biosimilars company.
We drive access to medicines.
How? We specialize in the development of generic and biosimilar medicines. That means we develop more affordable versions of high-quality medicines once their key patents have expired.
Medicines that reach millions
Our broad global portfolio comprises about 1,300 quality generic and biosimilar medicines. In 2024 we provided more than 900 million patient treatments, generating more than USD 19 billion in direct savings for US and European healthcare systems alone, improving healthcare by freeing up resources and resulting in a total social impact estimated at around USD 400 billion worldwide.
